Cartesian Therapeutics (RNAC) Non-Current Debt (2015 - 2023)

Cartesian Therapeutics (RNAC) has 8 years of Non-Current Debt data on file, last reported at $13.8 million in Q2 2023.

• Non-Current Debt for Q2 2023 came in at $13.8 million, down 39.09% year-over-year; the trailing twelve-month figure through Jun 2023 was $13.8 million (down 39.09% YoY), and the FY2022 annual result was $17.8 million, down 9.59% from the prior year.
• Non-Current Debt retreated to $13.8 million in Q2 2023 per RNAC's latest filing, from $16.2 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $25.0 million in Q1 2022 and troughed at $6.4 million in Q2 2020.
• A 4-year average of $20.0 million and a median of $21.3 million in 2021 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2021 and 2023: Non-Current Debt surged 255.57% in 2021, then plunged 39.09% in 2023.
• A 4-year view of Non-Current Debt shows it stood at $24.8 million in 2020, then fell by 20.65% to $19.7 million in 2021, then dropped by 9.59% to $17.8 million in 2022, then retreated by 22.48% to $13.8 million in 2023.
• Business Quant data shows RNAC's Non-Current Debt at $13.8 million in Q2 2023, $16.2 million in Q1 2023, and $17.8 million in Q4 2022.